IN2012DN02782A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN02782A IN2012DN02782A IN2782DEN2012A IN2012DN02782A IN 2012DN02782 A IN2012DN02782 A IN 2012DN02782A IN 2782DEN2012 A IN2782DEN2012 A IN 2782DEN2012A IN 2012DN02782 A IN2012DN02782 A IN 2012DN02782A
- Authority
- IN
- India
- Prior art keywords
- antagonist
- beta
- patient
- side effects
- comprises administering
- Prior art date
Links
- 238000000034 method Methods 0.000 abstract 2
- 206010020853 Hypertonic bladder Diseases 0.000 abstract 1
- 208000009722 Overactive Urinary Bladder Diseases 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 238000002648 combination therapy Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000003149 muscarinic antagonist Substances 0.000 abstract 1
- 208000020629 overactive bladder Diseases 0.000 abstract 1
- 229940126158 β3 adrenergic receptor agonist Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24938609P | 2009-10-07 | 2009-10-07 | |
| PCT/US2010/050328 WO2011043942A1 (en) | 2009-10-07 | 2010-09-27 | Combination therapy using a beta 3 adrenergic receptor agonist and an antimuscarinic agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2012DN02782A true IN2012DN02782A (cg-RX-API-DMAC7.html) | 2015-09-18 |
Family
ID=43857059
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2782DEN2012 IN2012DN02782A (cg-RX-API-DMAC7.html) | 2009-10-07 | 2010-09-27 |
Country Status (15)
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2011285928B9 (en) * | 2010-08-03 | 2018-08-02 | B3Ar Therapeutics, Inc. | Combinations of beta - 3 adrenergic receptor agonists and muscarinic receptor antagonists for treating overactive bladder |
| US9522129B2 (en) | 2010-08-03 | 2016-12-20 | Velicept Therapeutics, Inc. | Pharmaceutical Combination |
| US9907767B2 (en) | 2010-08-03 | 2018-03-06 | Velicept Therapeutics, Inc. | Pharmaceutical compositions and the treatment of overactive bladder |
| EP2706997B1 (en) * | 2011-05-10 | 2019-03-27 | TheraVida, Inc. | Combinations of solifenacin and pilocarpine for the treatment of overactive bladder |
| JP6063948B2 (ja) | 2011-10-27 | 2017-01-18 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | ベータ３アゴニストおよび中間体を製造するプロセス |
| US9809536B2 (en) | 2011-10-27 | 2017-11-07 | Merck Sharp & Dohme Corp. | Process for making beta 3 agonists and intermediates |
| SG11201404776PA (en) * | 2012-02-09 | 2014-09-26 | Altherx Inc | Combination of muscarinic receptor antagonists and beta- 3 adrenoceptor agonists for treating overactive bladder |
| HUE045260T2 (hu) | 2013-03-15 | 2019-12-30 | Merck Sharp & Dohme | Eljárás béta 3 antagonisták és köztitermékeik elõállítására |
| AU2014293141A1 (en) * | 2013-07-23 | 2016-02-18 | Serenity Pharmaceuticals Llc | Methods and compositions comprising desmopressin in combination with a beta-3 adrenergic receptor agonist |
| JP2017535567A (ja) | 2014-11-20 | 2017-11-30 | アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ | アルファ−アドレナリン受容体拮抗薬と組み合わせたデスモプレシンを含む方法及び組成物 |
| CN107205964A (zh) | 2014-12-03 | 2017-09-26 | 威力塞帕特治疗股份有限公司 | 使用调节释放索拉贝隆用于下尿路症状的组合物和方法 |
| WO2017015349A1 (en) * | 2015-07-20 | 2017-01-26 | Chase Pharmaceuticals Corporation | Muscarinic combination of a selective m2-antagonist and a peripheral non-selective antagonist for treating hypocholinergic disorders |
| PT3365321T (pt) | 2015-10-23 | 2024-01-12 | B3Ar Therapeutics Inc | Zwiterião de solabegron e suas utilizações |
| WO2018039159A1 (en) * | 2016-08-22 | 2018-03-01 | Chase Pharmaceuticals Corporation | Muscarinic m2-antagonist combination |
| US12102638B2 (en) | 2017-06-06 | 2024-10-01 | Urovant Sciences Gmbh | Use of vibegron to treat overactive bladder |
| KR20250095747A (ko) * | 2017-06-06 | 2025-06-26 | 유로반트 사이언시즈 게엠베하 | 과민성 방광의 치료를 위한 비베그론의 투약 |
| CN111556753A (zh) * | 2017-12-21 | 2020-08-18 | 杏林制药株式会社 | 用于夜间尿频的治疗剂 |
| BR112021010856A2 (pt) | 2018-12-05 | 2021-11-16 | Urovant Sciences Gmbh | Vibegron para o tratamento de sintomas de bexiga hiperativa |
| CN115850286B (zh) * | 2022-12-05 | 2023-08-22 | 奥锐特药业(天津)有限公司 | 一种维贝格龙中间体及其制备方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2789076B1 (fr) * | 1999-02-02 | 2001-03-02 | Synthelabo | Derives de alpha-azacyclomethyl quinoleine, leur preparation et leur application en therapeutique |
| GB2356197A (en) * | 1999-10-12 | 2001-05-16 | Merck & Co Inc | Amide derivatives as beta 3 agonists |
| WO2003024483A1 (fr) * | 2001-09-11 | 2003-03-27 | Fujisawa Pharmaceutical Co., Ltd. | Potentialisateur d'effets inhibiteurs sur la frequence des mictions et l'incontinence urinaire |
| TWI295669B (en) * | 2002-10-30 | 2008-04-11 | Theravance Inc | Substituted 4-amino-1-(pyridylmethyl) piperidine and related compounds |
| US20040248979A1 (en) * | 2003-06-03 | 2004-12-09 | Dynogen Pharmaceuticals, Inc. | Method of treating lower urinary tract disorders |
| EP1804778A1 (de) * | 2004-10-18 | 2007-07-11 | Boehringer Ingelheim International GmbH | Verwendung eines beta-3-agonisten zur behandlung von beschwerden der prostata und des unteren urogenitaltrakts |
| AU2008233232A1 (en) * | 2007-03-29 | 2008-10-09 | Merck Sharp & Dohme Corp. | Combination therapy for the treatment-of lower urinary tract symptoms |
| PE20091825A1 (es) * | 2008-04-04 | 2009-12-04 | Merck & Co Inc | Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3 |
-
2010
- 2010-09-27 BR BR112012007829A patent/BR112012007829A2/pt not_active IP Right Cessation
- 2010-09-27 US US13/500,574 patent/US20120202819A1/en not_active Abandoned
- 2010-09-27 WO PCT/US2010/050328 patent/WO2011043942A1/en not_active Ceased
- 2010-09-27 EP EP10822429.6A patent/EP2485595A4/en not_active Withdrawn
- 2010-09-27 IN IN2782DEN2012 patent/IN2012DN02782A/en unknown
- 2010-09-27 JP JP2012533204A patent/JP5738871B2/ja active Active
- 2010-09-27 CA CA2774992A patent/CA2774992A1/en not_active Abandoned
- 2010-09-27 KR KR1020127008961A patent/KR20120093859A/ko not_active Withdrawn
- 2010-09-27 NZ NZ599233A patent/NZ599233A/xx not_active IP Right Cessation
- 2010-09-27 RU RU2012118668/13A patent/RU2012118668A/ru not_active Application Discontinuation
- 2010-09-27 CN CN2010800550891A patent/CN102638987A/zh active Pending
- 2010-09-27 MX MX2012004134A patent/MX2012004134A/es not_active Application Discontinuation
- 2010-09-27 AU AU2010303811A patent/AU2010303811B2/en not_active Ceased
-
2012
- 2012-03-20 IL IL218756A patent/IL218756A0/en unknown
- 2012-04-05 ZA ZA2012/02520A patent/ZA201202520B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2485595A4 (en) | 2014-03-12 |
| ZA201202520B (en) | 2012-12-27 |
| US20120202819A1 (en) | 2012-08-09 |
| KR20120093859A (ko) | 2012-08-23 |
| BR112012007829A2 (pt) | 2015-09-22 |
| JP2013507363A (ja) | 2013-03-04 |
| RU2012118668A (ru) | 2013-11-20 |
| JP5738871B2 (ja) | 2015-06-24 |
| IL218756A0 (en) | 2012-06-28 |
| CA2774992A1 (en) | 2011-04-14 |
| NZ599233A (en) | 2013-04-26 |
| EP2485595A1 (en) | 2012-08-15 |
| AU2010303811A1 (en) | 2012-04-19 |
| CN102638987A (zh) | 2012-08-15 |
| AU2010303811B2 (en) | 2013-01-24 |
| WO2011043942A1 (en) | 2011-04-14 |
| MX2012004134A (es) | 2012-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2012DN02782A (cg-RX-API-DMAC7.html) | ||
| MX2011008450A (es) | Agonistas y antagonistas del receptor s1p5, y metodos de uso de los mismos. | |
| BR112012025017A2 (pt) | métodos para melhorar a qualidade do sono. | |
| AU2008232453A8 (en) | Methods and compositions for reduction of side effects of therapeutic treatments | |
| WO2011014255A8 (en) | Treatment of crohn's disease with laquinimod | |
| WO2009129432A3 (en) | Alpha adrenergic receptor agonists for treatment of pain and/or inflammation | |
| MX2009011898A (es) | Composiciones y metodos para tratar trastornos asociados con retencion de sal o fluido. | |
| MX2010005331A (es) | Composiciones y metodos para tratamiento de purpura. | |
| NZ600125A (en) | Methods of treating or preventing acute erythema | |
| MX337614B (es) | Tratamiento de lupus nefritis usando laquinimod. | |
| EP4275752A3 (en) | Treatment of addiction and impulse-control disorders using pde7 inhibitors | |
| WO2009129494A3 (en) | Alpha and beta adrenergic receptor agonists for treatment of pain and/or inflammation | |
| BR112012022064A2 (pt) | tratamento de artrite lúpica usando laquinimod | |
| PH12013501244A1 (en) | A combination of an opioid agonist and an opioid antagonist in the treatment of parkinson's disease | |
| MY165160A (en) | TREATMENT OF MYOCARDIAL INFARCTION USING TGF-ß ANTAGONISTS | |
| PH12013500221A1 (en) | Combinations of beta - 3 adrenergic receptor agonists and muscarinic receptor antagonists for treating overactive bladder | |
| MX2013003638A (es) | Tratamiento en combinacion para rosacea. | |
| EP2490700A4 (en) | EXTERNAL SKIN CARE COMPOSITION COMPRISING SALT AND SUGAR AS ACTIVE INGREDIENTS FOR PREVENTING AND TREATING VAGINOSIS AND USE THEREOF | |
| WO2009052073A3 (en) | Method of treating sensorimotor disorders with alpha-2 adrenergic receptor agonists | |
| MX341660B (es) | Agonista del receptor de ghrelina para el tratamiento de caquexia. | |
| MX2009009332A (es) | Antagonista del receptor de mineralocorticoides para el tratamiento de endometriosis. | |
| TN2011000457A1 (en) | Method or system using biomarkers for the monitoring of a treatment | |
| WO2009052075A3 (en) | Method of treating motor disorders with alpha-2b adrenergic receptor agonists | |
| WO2011109743A3 (en) | Synergistic effects of combinations of buprenorphine and opioids for the treatment of pain | |
| MX2021011289A (es) | Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas. |